# Healthcare Global Enterprises (NSE: HCG) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/HCG · Pivot · prices to 22 Oct 2026

Healthcare Global Enterprises (NSE: HCG) closed at ₹552.00 on 22 Oct 2026, up 0.60% on the day. With a market capitalisation of ₹8,241 Cr, it ranks 604th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

Its return on equity was 1.0% in FY26. Over the past year the share price has fallen 19.8%. Its 52-week range is ₹513.30 (30 Mar 2026) to ₹799.70 (24 Oct 2025); the last close is 31.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹695 Cr (+13.4% year on year) and net profit ₹16 Cr (+193.0%), on a consolidated basis. Promoters held 64.21% of the company as of 30 Jun 2026; 5.17% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹552.00 |
| Market cap | ₹8,241 Cr |
| ROE | 1.0% (FY26) |
| ROCE | 8.5% (FY26) |
| Debt to equity | 0.68 |
| 52-week high | ₹799.70 (24 Oct 2025) |
| 52-week low | ₹513.30 (30 Mar 2026) |
| 1-year return | −19.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹695 Cr | +13.4% | ₹16 Cr | +193.0% | ₹0.92 |
| Q4 FY26 | ₹652 Cr | +11.5% | ₹4 Cr | −48.7% | ₹0.15 |
| Q3 FY26 | ₹633 Cr | +13.3% | −₹8 Cr | −214.6% | −₹0.68 |
| Q2 FY26 | ₹647 Cr | +16.9% | ₹20 Cr | −1.7% | ₹1.16 |
| Q1 FY26 | ₹613 Cr | +16.7% | ₹5 Cr | −61.1% | ₹0.34 |
| Q4 FY25 | ₹585 Cr | +18.3% | ₹7 Cr | −70.7% | ₹0.53 |
| Q3 FY25 | ₹559 Cr | +18.9% | ₹7 Cr | +99.1% | ₹0.50 |
| Q2 FY25 | ₹554 Cr | +13.7% | ₹21 Cr | +91.9% | ₹1.29 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,223 Cr | ₹48 Cr |
| FY24 | ₹1,908 Cr | ₹41 Cr |
| FY23 | ₹1,691 Cr | ₹18 Cr |
| FY22 | ₹1,398 Cr | ₹40 Cr |
| FY21 | ₹1,013 Cr | −₹221 Cr |
| FY20 | ₹1,096 Cr | −₹113 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 64.21%
- Foreign institutions: 2.74%
- Domestic institutions: 19.20%
- Non-institutions: 13.85%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Viyash Scientific](https://app.pivotnow.in/stock/VIYASH) | ₹214.90 | ₹9,388 Cr | 53.6 | — |
| [Strides Pharma Science](https://app.pivotnow.in/stock/STAR) | ₹1,017.30 | ₹9,377 Cr | 16.9 | — |
| [Yatharth Hospital & Trauma Care Services](https://app.pivotnow.in/stock/YATHARTH) | ₹932.10 | ₹8,981 Cr | 51.2 | — |
| [Suven Life Sciences](https://app.pivotnow.in/stock/SUVEN) | ₹276.60 | ₹7,816 Cr | — | — |
| [Sanofi Consumer Healthcare India](https://app.pivotnow.in/stock/SANOFICONR) | ₹3,325.80 | ₹7,660 Cr | 29.7 | — |
| [Aarti Pharmalabs](https://app.pivotnow.in/stock/AARTIPHARM) | ₹838.00 | ₹7,599 Cr | 43.6 | — |

## Questions and answers

### What is the share price of Healthcare Global Enterprises today?

Healthcare Global Enterprises (NSE: HCG) last closed at ₹552.00 on 22 Oct 2026. Its 52-week high is ₹799.70 and its 52-week low is ₹513.30.

### What is the market cap of Healthcare Global Enterprises?

Healthcare Global Enterprises' market capitalisation is ₹8,241 Cr (₹8,241 Cr) at the 22 Oct 2026 close, ranking 604th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Healthcare Global Enterprises?

Return on equity was 1.0% in FY26 and return on capital employed was 8.5% in FY26 (consolidated figures).

### Is Healthcare Global Enterprises a debt-free company?

No. Healthcare Global Enterprises' debt-to-equity ratio was 0.68 in FY26, with total debt of ₹599 Cr.

### What were Healthcare Global Enterprises' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Healthcare Global Enterprises reported revenue of ₹695 Cr, +13.4% year on year, and net profit of ₹16 Cr, +193.0% year on year.

### How has Healthcare Global Enterprises stock performed over the last year?

Healthcare Global Enterprises' share price has fallen 19.8% over the past year, −17.6% over three months and −21.1% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Healthcare Global Enterprises?

As of 30 Jun 2026: promoters 64.21%, foreign institutions 2.74%, domestic institutions 19.20%, non-institutions 13.85%. 5.17% of promoter shares were pledged.

### Who are Healthcare Global Enterprises' competitors?

The listed Pharma & Healthcare companies closest to Healthcare Global Enterprises by market cap are Viyash Scientific, Strides Pharma Science, Yatharth Hospital & Trauma Care Services, Suven Life Sciences, Sanofi Consumer Healthcare India and Aarti Pharmalabs.

### Is Healthcare Global Enterprises a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Healthcare Global Enterprises' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HCG against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.